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This manuscript reports the consensus statements regarding the design and conduct of clinical trials in patients with newly
diagnosed and recurrent epithelial ovarian cancer (EOC), following deliberation at the Fifth Ovarian Cancer Consensus
Conference (OCCC), held in Tokyo in November 2015. Three important questions were identified for discussion prior to the
meeting and achieved consensus during the meeting: (i) What are the most important factors to be evaluated prior to initial
therapy? (ii) What are the most important factors to be evaluated specifically in recurrent disease? (iii) Are there specific
considerations for special patient subpopulations? In addition, we report a list of important unmet needs compiled during the
consensus process, which is intended to guide future research initiatives.
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Introduction
At the 5th Ovarian Cancer Consensus Conference of the
Gynecologic Cancer InterGroup (GCIG) held in Tokyo, Japan, in
November 2015, representatives of 29 cooperative research
groups studying gynaecologic cancers gathered to establish inter-
national consensus on issues critical to the conduct of large
randomized trials. The process focused on a series of predeter-
mined questions. Group A addressed six questions regarding
clinical and biologic factors in patients with newly diagnosed and
recurrent EOC.
The consensus statements for group A are presented in
Tables 1–3; all statements achieved unanimous consensus. While
achieving complete consensus, a list of important unmet needs
was also compiled, presented in Table 4. The statements are rec-
ommendations for development of clinical trials, to be adapted,
as appropriate, to the clinical setting (including local circum-
stances), specific agents under investigation, and study
objectives.
What are the most important factors to be
evaluated prior to initial therapy?
Clinical markers
Clinical trials addressing primary therapy of EOC require consid-
eration of prognostic or predictive factors potentially confound-
ing the interpretation of study results (Table 1).
FIGO (International Federation of Gynecology and Obstetrics)
surgical stage provides a standardized basis for comparing EOC
patients. The third OCCC stated that ‘surgical staging should be
mandatory and performed by a gynaecologic oncologist’, again
affirmed at the 4th OCCC [1]. In 2014, FIGO staging was
updated, reflecting that EOC comprises at least five distinct types:
High Grade Serous Carcinoma (HGSC), Ovarian Endometrioid
Adenocarcinoma (OEA), Clear Cell Carcinoma, Ovarian
Mucinous Carcinoma (OMC) and Low Grade Serous Carcinoma
(LGSC) [2]. The majority (70%) of EOC are HGSC, however, site
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of origin was acknowledged to include the fallopian tube, and
possibly the peritoneal surface, in the latest FIGO update [2]. The
OCCC recognizes that surgical pathologic stage, with both pri-
mary cytoreductive surgery (PCS) and interval cytoreductive
surgery (ICS) following neoadjuvant chemotherapy (NACT),
might serve for stratification in study design.
After surgical stage, the extent of residual disease (RD) follow-
ing PCS surgery is the next most important prognostic factor to
Table 1. What are the most important factors to be evaluated prior to initial therapy?
Prognostic factors
• FIGO stage, surgical pathologic (applies to Ov, FT and P)
• Cytoreduction status (primary complete resection versus other)
• Primary treatment modality (surgery versus NACT)
• Performance status and associated variables
• Tumour markers (e.g. CA-125) documented prior to therapy
• Country or geographic region of treatment
Pathology
• Histopathology remains the gold standard for the classification of epithelial ovarian (FIGO: Ov, FT, P) cancer subgroups
• In NACT, tumour grading (and typing) should be based on the pre-chemotherapy biopsy
• Binary grading of serous carcinoma (low-grade and high-grade), with distinction of micropapillary carcinoma
• Binary grading is favoured for endometrioid carcinoma (with assignment of FIGO grade 1 to low-grade, and 2–3 to high-grade)
• Carcinosarcomas are regarded as carcinomas
• Carcinosarcoma, clear cell carcinoma and undifferentiated carcinoma should not be graded
• Mucinous carcinoma should be graded
• Access to archival tumour specimens should be documented and maintained
Biomarkers
• Germline mutation testing to include BRCA1/2 is recommended for all patients enrolled on clinical trials
• Stratification (if possible) should be performed and knowledge of mutation status should be incorporated into primary endpoint analysis
• Somatic mutation analysis for BRCA 1/2 is recommended
• Predictive biomarkers for targeted agents to be included as companion diagnostics
Table 2. What are the most important factors to be evaluated specifically in recurrent disease?
Clinical-pathologic markers
• Treatment-free interval following primary chemotherapy
• With reference to last dose of primary platinum agent (PFI)
• Report as a continuous variable
• Less robust markers include acquired resistance following platinum-based therapy for recurrent disease
• Report last dose of non-platinum therapy, maintenance therapy (particularly anti-angiogenic agents or PARPi)
• Outcome following most recent cytoreductive surgery
• Presence of non-measurable versus RECIST-measurable disease
• Additional recommendations
• Separate clinical trials, if available, should be utilized for different histological subtypes, although trials can include multiple subtypes
• Collection of tumour specimens at relapse is encouraged
Table 3. Are there specific considerations for special patient subpopulations?
Race/ethnicity
• Collection, reporting and analysis of race/ethnicity categories should be incorporated in future trials
• Emerging data support differences in clinical outcomes in relationship to race/ethnicity, however, pharmacogenomics markers have not been defined,
and these population-based data are not sufficient to recommend stratification
• As data are validated within specific populations, race/ethnicity could become a stratification factor within individual studies
Frail and elderly
• Older age should not be an exclusion criterion in ovarian cancer trials
• Any limitations to eligibility criteria based on performance status, comorbidities, and prior malignancies should be justified by the trial design
• Clinical trials in ovarian cancer should include measures from the geriatric assessment domains
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be considered for stratification. Several aspects beyond surgical
skill and effort influence RD status, including patient medical co-
morbidities, tumour biology and local institutional resources.
Those patients who achieve optimal cytoreduction, without
macroscopic residual disease (MRD) have been shown to achieve
better overall survival (OS) relative to patients with macroscopic
RD [3, 4]. Stage for stage, the absence of macroscopic RD has
been shown to confer a large OS benefit compared to those pa-
tients with RD [5–7]. MRD at PCS is predictive of shorter time to
first (Hazard Ratio (HR) 1.50 [1.31–1.72]) and second (HR 1.48
[1.22–1.80]) recurrence [8]. When stratifying by RD, the OCCC
agreed that cytoreduction status be reported as primary complete
resection (PCR) of all visible disease versus other, moving away
from tumour measurements of<1 cm versus>1 cm. While
groups might choose to report the extent of residual disease and
outcomes according to previous definitions, the presence of RD,
irrespective of size, confers a poorer survival benefit relative to
complete cytoreduction. Need for accuracy and standardization
in reporting the extent of RD was recognized as an unmet goal.
Various measurement tools have been reported; scoring of RD
has largely been subjective, without objective verification [9–12].
When disease status is assessed by postoperative computed tom-
ography (CT), it can be discordant from surgical reports and
potentially of independent prognostic value, however, there
are currently insufficient data mandating postoperative imaging
[11, 12].
Primary treatment modality has also become an important fac-
tor to consider for stratification. Two randomized controlled tri-
als have shown that ICS is not inferior to PCS among patients
with advanced disease. Criticism of these studies has centred on
poor overall survival and low levels of complete and optimal
(<1 cm) cytoreduction achieved with PCS, raising questions
about surgical effort and institutional expertise. The higher opti-
mal cytoreduction rates achieved following NACT compared
with PCS (CHORUS 73% versus 41%, EORTC 80.6% versus
41.6%) did not translate into a survival benefit [11, 12]. Neither
the assessment of pathologic response following NACT nor the
minimum surgical requirements for ICS have been standardized.
The clinical impact of complete cytoreduction post-NACT is
likely to be less robust than complete cytoreduction with PCS.
Retrospective series have suggested that improved survival is
possible with PCS, particularly when incorporating radical surgi-
cal techniques [5–7, 13–16]. It remains difficult to control for se-
lection bias in retrospective data. Other studies have suggested
that tumour biology and initial tumour burden remain import-
ant, even with maximum surgical effort [17, 18]. These studies
also highlight the need to develop better criteria to guide the se-
lection of patients for NACT or PCS.
Performance status (PS) and associated variables should be
utilized as stratification points (SP), depending on the trial de-
sign. In the CHORUS study, designed for co-analysis with
EORTC 55971, anticipated OS at 3 years in the primary surgery
arm was 50%, but actual median OS was only 22–24 months.
Explanations for this discrepancy included a relatively poor PS
among study participants (19% PS grade 2 or 3) and an older pa-
tient population (median age 65 years). PS and other variables
associated with comorbidities (e.g. nutritional status) aid inter-
pretation of study results and should be considered in future trial
design [19, 20].
Prior to instituting therapy, the importance of documenting
tumour markers was affirmed. Traditional tumour markers have
included CA-125 and carcinoembryonic antigen (CEA), the latter
to exclude gastrointestinal primary. While acknowledging that
CA-125 is not truly ‘tumour-specific’, an analysis of seven GOG
studies found that pre-treatment CA-125 level was an independ-
ent predictor of progression-free survival (PFS), especially in pa-
tients with serous or endometrioid histology and microscopic
residual disease [21].
Another promising tumour marker is Human Epididymis
Protein 4 (HE4), shown to have good sensitivity and specificity in
EOC, both at initial diagnosis (differentiating EOC from benign)
and in documentation of recurrence [22–24]. A failure of HE4 to
normalize at completion of treatment is an indicator of poor
prognosis [24, 25]. Documentation of appropriate pre-treatment
tumour markers should be incorporated in future trials of pri-
mary therapy.
Country/region of treatment was determined to be an import-
ant potential stratification factor, recognizing differences in race,
ethnicity, local resources and clinical practice. The EORTC 55971
study showed widespread variations in optimal PCS rates by
country [26]. In the same study, however, regional OS did not
correlate with cytoreduction rates, with patients from regions
with the lowest rates of optimal cytoreduction achieving the best
survival [27]. In the SCOTROC-1 study, patients from the UK
with no MRD had less favourable PFS relative to non-UK patients
[28]. Nuances in care and patient selection will impact outcomes
from apparent standardized treatments. Consider country or re-
gion of treatment as a stratification factor where appropriate.
Pathologic markers
Consistent with the fourth OCCC, histopathology remains the
gold standard for the classification of EOC cancer subgroups [1].
Table 4. Unmet needs to support future clinical research
• Potential role of intra-operative scoring and/or post-operative imaging to document residual disease
• Universal staging criteria in the context of NACT
• Chemotherapy response scores that can be incorporated in the primary endpoint analysis
• Standards for immunologic assessment, including lymphocyte infiltration scores, T cell subsets, PD-1/PD-L1, etc.
• There are important issues regarding the definition and categorization of race/ethnicity that would benefit from international harmonization
• Since older patients and/or those with compromised functional status are underrepresented in clinical trials, there is a need to define this population
and perform trials to evaluate standards for this subgroup
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Where required, diagnostic accuracy of histopathology can be
improved with standardized application of immunohistochemis-
try (IHC) [29]. For pathological reporting within randomized
clinical trials (RCT), histological subtype and grade should not be
reported separately. Following NACT, morphological features of
the tumour at ICS could differ greatly from the original tumour,
including necrosis, inflammation, fibrosis and altered differenti-
ation status [30]. The OCCC determined that tumour grading
(and typing) should be based on the pre-chemotherapy tissue bi-
opsy. For serous carcinoma, there was consensus recommending
a binary grading system, limited to HGSC and LGSC (incorporat-
ing micropapillary carcinoma). Discrimination between LGSC
and HGSC follows the degree of nuclear atypia in combination
with mitotic activity [31]. LGSC is characterized by frequent mu-
tations in KRAS, BRAF and ERBB2 genes and infrequent TP53
mutations [32]. Whereas TP53 mutations are rare in LGSC, they
are ubiquitous in HGSC. Absence of a loss-of-function molecular
alteration in TP53 is inconsistent with a diagnosis of HGSC [33,
34].
The OCCC recommends that in HGSC, the fallopian tubes be
intensively sampled using a Sectioning and Extensively
Examining of the Fimbriated End (SEE-FIM) protocol [35].
With serous tubal intraepithelial carcinoma (STIC) and wide-
spread peritoneal involvement, where ovarian surface involve-
ment or parenchymal involvement is<5 mm, these tumours
should be classified as tubal primaries.
When categorizing ovarian endometrioid adenocarcinoma
(OEA), adoption of a binary grading system was also recom-
mended. This differs from the 2014 WHO classification of female
reproductive organs and reporting standards endorsed by the
International Collaboration on Cancer Reporting (ICCR),
where OEA are graded identically to uterine endometrioid car-
cinomas – grade 1, 2 or 3 [36, 37]. FIGO grading of endometrioid
endometrial carcinoma reflects not only the presence of
high-grade cytological features but also the actual percentage of
high-grade solid tumour, which is less relevant in the setting of a
non-endometrial primary site. High-grade endometrioid tu-
mours demonstrate mutational profiles similar to HGSC har-
bouring TP53 mutations, while the low-grade tumours showed
distinct mutations in CTNNB1, PTEN and/or PIK3CA [38].
Mutations in the Wnt/Beta-cat signalling pathways present
in low-grade tumours were absent in high-grade endometrioid
carcinoma. The consensus recommends classifying FIGO grade
1 tumours to low-grade, and grades 2 and 3 to high-grade.
Clear cell carcinoma, carcinosarcoma and undifferentiated car-
cinoma should be classified as high-grade epithelial malignancies
[37]. Carcinosarcomas are included, despite having mixed epi-
thelial and mesenchymal components, attributed to epithelial–
mesenchymal transition [39]. Most OMC are of intestinal type,
arising through a continuum from benign to borderline to malig-
nant [31]. These are usually well to moderately differentiated
(grade 1 or 2) and can exhibit expansile (non-destructive) or
infiltrative (destructive) invasion, although controversy exists
about the ability to prognosticate based on pattern of invasion
[37]. According to WHO (2014), Mullerian and endocervical
type tumours, previously classified as mucinous, and now classi-
fied as seromucinous, are thought to be more closely related to
endometrioid tumours than to mucinous intestinal types [36].
Grading of OMC is recommended.
The importance of access to archival tumour specimens for fu-
ture molecular studies was affirmed. Study protocols should ac-
count for the documentation and maintenance of archival
specimens. One method endorsed by the ICCR is to record the
origin and designation of tissue blocks in the final pathology re-
port [37]. Collected specimens allow for extended correlative
studies, where bio-specimens are linked to clinical data.
Genomic biomarkers
For patients enrolled in clinical trials, germline mutation testing
to include BRCA1/2 was recommended, with stratification and
incorporation of mutation status into endpoint analysis. Many
series have shown that BRCA 1/2 mutation is associated with im-
proved outcomes [40]. One large aggregated analysis has sug-
gested that the advantage associated with BRCA1 mutations may
become less favourable over time [41]. The power of a long-term
retrospective analysis could be impacted by non-germline (som-
atic) mutations and other molecular factors within the BRCA
“wild-type” cohort. There was debate whether germline testing
should be limited to non-mucinous histologies; in view of the
risk of misclassification, as well as concordance with published
guidelines, it was recommended that within a trial, patients with
EOC should undergo germline testing [40].
The consensus recommends somatic mutation analysis of tu-
mour samples. Loss of BRCA function secondary to somatic mu-
tations in OC accounts for 7%–13% of BRCA mutations in
HGSC [42–44]. Somatic analysis from The Cancer Genome Atlas
(TCGA) project demonstrated that approximately 50% of HGSC
have associated homologous recombination deficiency (HRD),
potentially targetable with poly (ADP-ribose) polymerase
(PARP) inhibitors [45]. Extending BRCA1/2 testing to include
somatic mutation analysis was recommended.
As validated predictive biomarkers become available, these
should be included as companion diagnostics. Several potential
biomarkers were discussed. The creation of an HRD score based
on loss of heterozygosity (LOH) correlates with mutations in
BRCA1/2 and other genes, while accurately predicting both OS
and PFS [46]. Regardless of histology, HRD defects are associated
with both platinum sensitivity and improved OS [44]. Another
HRD signature based on LOH correlates with response to PARP
inhibitor [45, 47].
A potentially targetable biomarker is the overexpression of
Cyclin E1 (CCNE-1) seen in OC [48]. CCNE-1 amplification cor-
relates with shorter PFS when PCS is followed by platinum/tax-
ane chemotherapy, and it correlates with platinum resistance in
HGSC [49, 50]. A third potential biomarker is represented by
intratumoural T-cells in EOC tissue. In patients with stage III/IV
EOC, the presence of intratumoural T cells correlates with im-
proved PFS and OS [51]. This illustrates another area of unmet
need, where immunologic functional scoring might guide the de-
velopment of immunologic interventions.
What are the most important factors to be
evaluated specifically in recurrent disease?
The OCCC addressed factors to consider in the design of phase
III trials in the recurrent setting. Treatment-free interval (TFI)
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following primary chemotherapy was identified as the most im-
portant clinical factor. As treatment with a platinum-based regi-
men remains standard of care in the primary setting, the
platinum free interval (PFI) should be documented and utilized
to determine eligibility or serve as a stratification factor (Table 2).
Several studies have shown a differential impact of subsequent
treatments based on the PFI. AGO-OVAR 2.5 comparing gemci-
tabine/carboplatin versus carboplatinum showed differential PFS
(7.9 versus 9.7 months) based on initial PFI, between partially
platinum sensitive patients (6–12 months) and those who were
platinum sensitive (>12 months) [52]. Penultimate platinum
treatment should be considered at randomization. The analysis
by Hanker et al. [8], addressing effectiveness of chemotherapy at
recurrence, included patients on trials in the primary setting to
characterize PFS/OS from the second to the sixth lines of therapy.
PFI following first-line treatment was strongly prognostic for PFS
up to the third recurrence (OR 0.56 [0.5–0.63] at first recurrence;
OR 0.76 [0.64–0.9] at second recurrence). In the CALYPSO trial,
a subset of patients with a prolonged TFI>24 months was ana-
lysed separately, reflecting their different tumour biology [53].
Considering the linear relationship between extended PFI
and platinum sensitivity, we recommend reporting PFI following
primary chemotherapy as a continuous variable, rather than
adopting an arbitrary definition of ‘platinum-sensitive’ or ‘plat-
inum-resistant’ disease based on a single fixed time point (such as
6 months). Future trials could define eligibility or patient cohorts
according to any appropriate PFI, depending on the nature of the
study, and may, therefore, not be limited to a fixed 6-month
window.
Platinum-based therapy (PBT) remains the most active agent
in the management of EOC, and primary PFI clearly provides im-
portant prognostic and predictive information. Many patients re-
ceive multiple lines of PBT, and the time interval following the
most recent PBT can also provide prognostic information, due to
acquired resistance and clonal evolution associated with inter-
vening non-platinum treatments.
A variety of non-platinum agents have been integrated with
conventional therapy, and other prognostic/predictive markers
are needed to guide treatment decisions in the management of re-
currence. Several trials have affirmed that targeting the vascular
endothelial growth factor (VEGF) improves clinical outcomes as
maintenance post-chemotherapy or in combination with chemo-
therapy for recurrence [54–60]. PARP inhibitors have demon-
strated improved PFS as single agents in the management of
recurrence and as maintenance following chemotherapy [60].
Recognizing emerging treatment strategies, the OCCC also rec-
ommended that the last dose of non-platinum agents, including
maintenance therapy, be recorded.
Secondary (or subsequent) cytoreductive surgery has been in-
creasingly utilized in selected patients with recurrent ovarian can-
cer, and the OCCC recommends stratification based on the
outcome of the most recent cytoreductive surgery. Complete re-
section was associated with prolonged survival in the recurrent
setting in the exploratory DESKTOP OVAR trial (45.2 versus
19.7 months, HR 3.71, P< 0.0001), also confirmed elsewhere
[61, 62].
With recurrence, the presence of non-measurable versus
RECIST (response evaluation criteria in solid tumours)-
measurable disease should be documented, including small solid/
cystic lesions and fluid collections as well as diffuse tumour im-
plantation on vital organs without measurable solid components,
depending on study eligibility. Solid tumour response was
defined in RECIST version 1.1 [63], and RECIST guidelines for
progression of disease can be applied to patients with non-
measurable disease at enrolment. GCIG guidelines to determine
tumour response and progression using CA-125 exist, and al-
though these have not been accepted as primary endpoints by
regulatory authorities, they can be utilized to provide supporting
data [64].
Histological subtype remains an important factor to guide en-
rolment in sub-type specific trials, or as a SP. In light of different
genetic risk factors, molecular abnormalities and precursor le-
sions, as well as variable response to chemotherapy and targeted
agents across histologies, histotype must be considered [65].
Collection of tumour specimens at relapse is encouraged, with an
emphasis on paired samples collected at the outset and at recur-
rence, enhancing the study of molecular targeting and acquired
resistance.
Are there specific considerations for special
patient subpopulations?
Race and ethnicity
Differences in outcome of cancer treatments attributable to race/
ethnicity are becoming recognized, the result of both biological
and environmental interactions [66] (Table 3). When comparing
treatment and survival between Asian and white women with
EOC in the US, age, stage of presentation, as well as histological
subtype/grade differed between the groups [67]. Dividing Asians
into immigrant versus US-born, 5-year disease-specific survival
favoured immigrant Asians compared with US-born Asians and
whites (55%, 52%, and 48%, respectively, P< 0.001). Increases in
5-year OS over the past 30 years seen in whites (36%–45%) have
been met with a decrease in blacks (43%–39%) over the same
time period [68]. A positive first line maintenance trial investigat-
ing pazopanib has shown inferior outcome in Asian patients
compared with placebo, meaning a drug could harm specific pa-
tient subgroups, even in a positive trial [69]. A separate study
examining potential racial disparities between blacks and whites
enrolled in GOG clinical trials found equivalent PFS between the
two groups (37.9 and 39.7, respectively, P> 0.05) [70].
The collection, reporting and analysis of race/ethnicity catego-
ries should be incorporated in future trials. Predefined and pro-
spective data collection minimizes confounding and strengthens
associations found in post hoc analysis of trial data. Race and eth-
nicity are differentially categorized by country and region; devel-
opment of universal standards was recognized as an unmet need,
limiting international data harmonization.
In a meta-analysis of RCTs treating advanced stage non-small
cell lung cancer, a difference in the overall response rate between
Asians and Caucasians was observed (65% versus 31%, P¼ 0.01),
where ethnicity was identified as the only independent predictor
of response to treatment by multivariable analysis [71]. Several
studies have shown associations or putative effects between
polymorphisms and outcome/toxicity. Attempts to validate
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a previously defined set of polymorphisms from the Scottish
Randomized Trial in Ovarian Cancer, no pharmacogenetics
markers for outcome or toxicity were identified [72]. Until more
data emerge, existing studies do not support stratification; as data
are validated within specific populations, race/ethnicity could be-
come a stratification factor within individual studies.
Frail and elderly patients
In the conduct of phase III trials in EOC, frail and elderly patients
have been underrepresented. Comorbidities and physiologic fac-
tors are predictive of outcomes and toxicity, compared to age;
older age should not be an exclusion criterion in EOC trials.
The improvements in cancer survival over the past decades
generally seen in younger patients have not translated to elderly
cohorts, with a widening gap of OS rates between younger and
more elderly cohorts [73, 74]. In Germany between 1979 and 2003,
age-specific OC survival remained stable for women age 75 and
over, yet OS steadily increased for women aged 15–54. Women
aged 55–74 experienced an increase from 1994 onwards, represent-
ing the highest age gradient seen across all tumours [75].
Outcomes for elderly patients may relate directly to the care
they receive, particularly when that care deviates from the stand-
ard. Surveillance, Epidemiology and End Results Program
(SEER) data investigating risk factors for early death show that
the largest risk factor for death at one year was receiving non-
standard treatment [76]. This is echoed by the German experi-
ence, where differential treatment in women over 70 was associ-
ated with differences in survival. Analysing patients enrolled in
phase III RCTs addressing first-line treatment, women>70
(10.7% of patients) were more likely to experience discontinu-
ation of their treatment and receive 4 or fewer cycles [77, 78].
Multivariate analysis of PFS in women 70 or older receiving 4 or
fewer cycles of chemotherapy was 2.3 (P< 0.001), translating
into a difference in PFS of 18.4 (P< 0.001) months and OS of
33.8 months (P< 0.001) [79].
Patients enrolled in clinical trials tend to have better outcomes
based on the need to meet eligibility requirements, with healthier
patients more likely to achieve enrolment. The results of some tri-
als then become poorly generalizable, as they are not addressing
the realities of patients seen in the real-world clinical domain [80,
81]. Apart from advanced age, OC patients may present with
comorbidities or poor PS, which will impact OS [20, 82]. While
prior cancer diagnosis is often an exclusion criterion from an
RCT out of concern that it might interfere with the current study,
no data exist which support this practice [83]. To improve
generalizability of trial results, with the goal to make trials avail-
able to the broadest population possible, any limitations to eligi-
bility criteria based on PS/comorbidities/prior malignancies
must be justified by the trial design.
Adequately comparing patients for trial inclusion requires vali-
dated measures to minimize confounding. While elderly patients
must be considered for inclusion as trials are developed, inclusion
based on the age alone is insufficient. In conjunction with age and
geriatric conditions, comorbidities, disability and physical re-
serve must be considered in consort. The goal is to differentiate
elderly patients who could receive standard treatment from frail
patients – those with low physiologic reserve – who are not candi-
dates for standard therapy and could benefit from a
comprehensive geriatric assessment (CGA) to help guide therapy
[84]. To date, measures of frailty have failed to achieve both the
high sensitivity and specificity required to ensure that patients
deemed fit enough for standard treatment truly are, and to differ-
entiate these patients from those who will benefit from a CGA
[84]. The consensus recommends that clinical trials in EOC
should include measures from geriatric assessment domains.
Unmet needs to support future clinical
research
In the process of assigning important SP throughout the consen-
sus process, unmet needs were identified as areas with potential
to enhance clinical research but which lack direction. In regards
to the issue of assessing residual disease at the time of debulking
surgery, the group sees a potential role for intra-operative scoring
[85] and/or post-operative imaging (see Clinical markers section)
to document RD (Table 4).
Universal staging criteria in the context of NACT are needed.
In CHORUS and EORTC 55971, women in the NACT arms were
staged clinically using imaging [3, 4]. No validated process exists
for documenting the extent of disease outside of surgery.
Treating patients with NACT will result in morphological
changes to the tumour. While attempts at quantifying the chemo-
therapy effect on tumour morphology have been undertaken,
none have proven to be prognostic. The International
Collaboration on Cancer Reporting has recently published a vali-
dated chemotherapy response score (CRS) with prognostic sig-
nificance for PFS [86]. There is a need for creation of a CRS that
can be incorporated in primary endpoint analysis and patho-
logical reporting.
Immunotherapy in OC represents a rapidly evolving treatment
domain, with an urgent need for the standardization of immuno-
logic assessment. Programmed cell death ligands (PD-1 and PD-
L1) and CD8þT cells are prognostic in OC, the former allowing
for immune evasion of tumour cells [87]. T cell infiltration into
OC tumour samples is associated with improved OS [51].
Standards for immunologic assessment, including lymphocyte
infiltration scores, T cell subsets and PD-1/PD-L1, are required
for comparison among studies and in order to allow for incorpor-
ation as SP in future studies.
There are important issues regarding definition and
categorization of race/ethnicity that would benefit from interna-
tional harmonization (see Race and ethnicity section). Older pa-
tients and/or those with compromised functional status are
underrepresented in clinical trials. There is a need to define this
population and perform trials to evaluate standards for this sub-
group (see Frail and elderly patients section).
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3. Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or pri-
mary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;
363(10): 943–953.
4. Kehoe S, Hook J, Nankivell M et al. Primary chemotherapy versus pri-
mary surgery for newly diagnosed advanced ovarian cancer (CHORUS):
an open-label, randomised, controlled, non-inferiority trial. Lancet 2015;
386(9990): 249–257.
5. Winter WE, Maxwell GL, Tian C et al. Prognostic factors for stage III
epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin
Oncol 2007; 25(24): 3621–3627.
6. Winter WE, Maxwell GL, Tian C et al. Tumor residual after surgical
cytoreduction in prediction of clinical outcome in stage IV epithelial
ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol
2008; 26(1): 83–89.
7. du Bois A, Reuss A, Pujade-Lauraine E et al. Role of surgical outcome as
prognostic factor in advanced epithelial ovarian cancer: a combined ex-
ploratory analysis of 3 prospectively randomized phase 3 multicenter tri-
als: by the Arbeitsgemeinschaft Gynaekologische Onkologie
Studiengruppe Ovarialkarzin. Cancer 2009; 115(6): 1234–1244.
8. Hanker LC, Loibl S, Burchardi N et al. The impact of second to sixth line
therapy on survival of relapsed ovarian cancer after primary taxane/
platinum-based therapy. Ann Oncol 2012; 23(10): 2605–2612.
9. Chi DS, Ramirez PT, Teitcher JB et al. Prospective study of the correl-
ation between postoperative computed tomography scan and primary
surgeon assessment in patients with advanced ovarian, tubal, and peri-
toneal carcinoma reported to have undergone primary surgical cytore-
duction to residual dis. J Clin Oncol 2007; 25(31): 4946–4951.
10. Sala E, Mannelli L, Yamamoto K et al. The value of postoperative/pread-
juvant chemotherapy computed tomography in the management of pa-
tients with ovarian cancer. Int J Gynecol Cancer 2011; 21(2): 296–301.
11. Lakhman Y, Akin O, Sohn MJ et al. Early postoperative CT as a prognos-
tic biomarker in patients with advanced ovarian, tubal, and primary peri-
toneal cancer deemed optimally debulked at primary cytoreductive
surgery. AJR Am J Roentgenol 2012; 198(6): 1453–1459.
12. Lorusso D, Sarno I, Di Donato V et al. Is postoperative computed tom-
ography evaluation a prognostic indicator in patients with optimally
debulked advanced ovarian cancer? Oncology 2014; 87(5): 293–299.
13. Aletti GD, Dowdy SC, Gostout BS et al. Quality improvement in the sur-
gical approach to advanced ovarian cancer: The Mayo Clinic Experience.
J Am Coll Surg 2009; 208(4): 614–620.
14. Shih KK, Chi DS. Maximal cytoreductive effort in epithelial ovarian can-
cer surgery. J Gynecol Oncol 2010; 21(2): 75–80.
15. Wimberger P, Wehling M, Lehmann N et al. Inuence of residual tumor
on outcome in ovarian cancer patients with FIGO stage IV disease: an
exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft
Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg
Oncol 2010; 17(6): 1642–1648.
16. Sehouli J, Savvatis K, Braicu E-I et al. Primary versus interval debulking
surgery in advanced ovarian cancer: results from a systematic single-
center analysis. Int J Gynecol Cancer 2010; 20(8): 1331–1340.
17. Hamilton C. a, Miller A, Miller C et al. The impact of disease distribution
on survival in patients with stage III epithelial ovarian cancer cytore-
duced to microscopic residual: a Gynecologic Oncology Group study.
Gynecol Oncol 2011; 122(3): 521–526.
18. Horowitz NS, Miller A, Rungruang B et al. Does aggressive surgery im-
prove outcomes? Interaction between preoperative disease burden and
complex surgery in patients with advanced-stage ovarian cancer: an ana-
lysis of GOG 182. J Clin Oncol 2015; 33(8): 937–943.
19. Aletti GD, Santillan A, Eisenhauer EL et al. A new frontier for quality of
care in gynecologic oncology surgery: multi-institutional assessment of
short-term outcomes for ovarian cancer using a risk-adjusted model.
Gynecol Oncol 2007; 107(1): 99–106.
20. Aletti GD, Eisenhauer EL, Santillan A et al. Identication of patient
groups at highest risk from traditional approach to ovarian cancer treat-
ment. Gynecol Oncol 2011; 120(1): 23–28.
21. Zorn KK, Tian C, McGuire WP et al. The prognostic value of pretreat-
ment CA 125 in patients with advanced ovarian carcinoma: a
Gynecologic Oncology Group study. Cancer 2009; 115(5): 1028–1035.
22. Manganaro L, Michienzi S, Vinci V et al. Serum HE4 levels combined
with CE CT imaging improve the management of monitoring women af-
fected by epithelial ovarian cancer. Oncol Rep 2013; 30(5): 2481–2487.
23. Granato T, Midulla C, Longo F et al. Role of HE4, CA72.4, and CA125 in
monitoring ovarian cancer. Tumour Biol 2012; 33: 1335–1339.
24. Braicu EI, Chekerov R, Richter R et al. HE4 expression in plasma correl-
ates with surgical outcome and overall survival in patients with rst ovar-
ian cancer relapse. Ann Surg Oncol 2014; 21(3): 955–962.
25. Schummer M, Drescher C, Forrest R et al. Evaluation of ovarian cancer
remission markers HE4, MMP7 and Mesothelin by comparison to the
established marker CA125. Gynecol Oncol 2012; 125(1): 65–69.
26. Atkins CD. Neoadjuvant chemotherapy or primary surgery in advanced
ovarian cancer. N Engl J Med 2010; 363(24): 2370–2372.
27. du Bois A, Marth C, Psterer J et al. Neoadjuvant chemotherapy cannot
be regarded as adequate routine therapy strategy of advanced ovarian
cancer. Int J Gynecol Cancer 2012; 22(2): 182–185.
28. Crawford SC, Vasey PA, Paul J et al. Does aggressive surgery only benet
patients with less advanced ovarian cancer? Results from an interna-
tional comparison within the SCOTROC-1 Trial. J Clin Oncol 2005;
23(34): 8802–8811.
29. Köbel M, Bak J, Bertelsen BI et al. Ovarian carcinoma histotype deter-
mination is highly reproducible, and is improved through the use of
immunohistochemistry. Histopathology 2014; 64(7): 1004–1013.
30. McCluggage WG, Lyness RW, Atkinson RJ et al. Morphological effects
of chemotherapy on ovarian carcinoma. J Clin Pathol 2002; 55: 27–31.
31. McCluggage WG. Morphological subtypes of ovarian carcinoma.
Pathology 2011; 43(5): 420–432.
32. Vang R, Shih L. Ovarian low-grade and high grade serous carcinoma.
Adv Anat Pathol 2010; 16(5): 267–282.
33. Vang R, Levine DA, Soslow RA et al. Molecular alterations of TP53 are a
dening feature of ovarian high-grade serous carcinoma: a rereview of
cases lacking TP53 mutations in The Cancer Genome Atlas Ovarian
Study. Int J Gynecol Pathol 2016; 35(1): 48–55.
34. Ahmed AA, Etemadmoghadam D, Temple J et al. Driver mutations in
TP53 are ubiquitous in high grade serous carcinoma of the ovary.
J Pathol 2010; 221(1): 49–56.
Review Annals of Oncology
708 | McGee et al. Volume 28 | Issue 4 | 2017
35. Singh N, Gilks CB, Wilkinson N, McCluggage WG. Assignment of pri-
mary site in high-grade serous tubal, ovarian and peritoneal carcinoma:
a proposal. Histopathology 2014; 65(2): 149–154.
36. Kurman RJ, Carcangiu ML, Herrington CSYR, WHO Classication of
Tumours of Female Reproductive Organs. 4th edition. Geneva: WHO
Press 2014.
37. McCluggage WG, Judge MJ, Clarke BA et al. Data set for reporting of
ovary, fallopian tube and primary peritoneal carcinoma: recommenda-
tions from the International Collaboration on Cancer Reporting (ICCR).
Modern Pathol 2015; 28(8): 1101–1122.
38. Wu R, Hendrix-Lucas N, Kuick R et al. Mouse model of human ovarian
endometrioid adenocarcinoma based on somatic defects in the Wnt/b-
Catenin and PI3K/Pten signaling pathways. Cancer Cell 2007; 11(4):
321–333.
39. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas
or metaplastic carcinomas? J Clin Pathol 2002; 55(5): 321–325.
40. Harter P, Johnson T, Berton-Rigaud D et al. BRCA1/2 mutations associ-
ated with progression-free survival in ovarian cancer patients in the
AGO-OVAR 16 study. Gynecol Oncol 2016; 140(3): 443–449.
41. Candido-dos-Reis FJ, Song H, Goode EL et al. Germline mutation in
BRCA1 or BRCA2 and ten-year survival for women diagnosed with epi-
thelial ovarian cancer. Clin Cancer Res 2015; 21(3): 652–657.
42. Hennessy BTJ, Timms KM, Carey MS et al. Somatic mutations in
BRCA1 and BRCA2 could expand the number of patients that benet
from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin
Oncol 2010; 28(22): 3570–3576.
43. McNeish IA, Oza AM, Coleman RL et al. Results of ARIEL2: a Phase 2
trial to prospectively identify ovarian cancer patients likely to respond to
rucaparib using tumor genetic analysis. J Clin Oncol 2015; 33(suppl):
abstr 5508.
44. Pennington KP, Walsh T, Harrell MI et al. Germline and somatic muta-
tions in homologous recombination genes predict platinum response
and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin
Cancer Res 2014; 20(3): 764–775.
45. Bell D, Berchuck A, Birrer M et al. Integrated genomic analyses of ovar-
ian carcinoma. Nature 2011; 474(7353): 609–615.
46. Abkevich V, Timms KM, Hennessy BT et al. Patterns of genomic loss of
heterozygosity predict homologous recombination repair defects in epi-
thelial ovarian cancer. Br J Cancer 2012; 107(10): 1776–1782.
47. Wang ZC, Birkbak NJ, Culhane AC et al. Proles of genomic instability in
high-grade serous ovarian cancer predict treatment outcome. Clin
Cancer Res 2012; 18(15): 5806–5816.
48. Nakayama N, Nakayama K, Shamima Y et al. Gene amplication
{CCNE}1 is related to poor survival and potential therapeutic target in
ovarian cancer. Cancer 2010; 116(11): 2621–2634.
49. Topp MD, Hartley L, Cook M et al. Molecular correlates of platinum re-
sponse in human high-grade serous ovarian cancer patient-derived
xenografts. Mol Oncol 2014; 8(3): 656–668.
50. Patch A-M, Christie EL, Etemadmoghadam D et al. Corrigendum:
whole-genome characterization of chemoresistant ovarian cancer.
Nature 2015; 527(7578): 398.
51. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recur-
rence, and survival in epithelial ovarian cancer. N Engl J Med 2003;
348(3): 203–213.
52. Psterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs.
carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA).
Results of a Gynecologic Cancer Intergroup randomized phase III trial
of the AGO OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol
2004; 22(Suppl): abstr 5005.
53. Mahner S, Meier W, du Bois A et al. Carboplatin and pegylated liposo-
mal doxorubicin versus carboplatin and paclitaxel in very platinum-
sensitive ovarian cancer patients: results from a subset analysis of the
CALYPSO phase III trial. Eur J Cancer 2015; 51(3): 352–358.
54. Aghajanian C, Blank SV, Goff BA et al. OCEANS: a randomized,
double-blind, placebo-controlled phase III trial of chemotherapy with or
without bevacizumab in patients with platinum-sensitive recurrent
epithelial ovarian, primary peritoneal, or fallopian tube. J Clin Oncol
2012; 30(17): 2039–2045.
55. du Bois A, Kristensen G, Ray-Coquard I et al. Standard rst-line chemo-
therapy with or without nintedanib for advanced ovarian cancer (AGO-
OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol 2016; 17(1): 78–79.
56. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizu-
mab in the primary treatment of ovarian cancer. N Engl J Med 2011;
365(26): 2473–2483.
57. Kim J-W, Mahner S, Wu L-Y et al. Pazopanib maintenance therapy in
East Asian women with advanced epithelial ovarian cancer: results from
AGO-OVAR16 and an East Asian study. Int J Gynecol Cancer 2015
November 19 [epub ahead of print].
58. Monk BJ, Poveda A, Vergote I et al. Anti-angiopoietin therapy with tre-
bananib for recurrent ovarian cancer (TRINOVA-1): a randomised,
multicentre, double-blind, placebo-controlled phase 3 trial. Lancet
Oncol 2014; 15(8): 799–808.
59. Perren TJ, Swart AM, Psterer J et al. A phase 3 trial of bevacizumab in
ovarian cancer. N Engl J Med 2011; 365(26): 2484–2496.
60. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhib-
ition: frequent durable responses in BRCA carrier ovarian cancer cor-
relating with platinum-free interval. J Clin Oncol 2010; 28(15):
2512–2519.
61. Harter P, du Bois A, Hahmann M et al. Surgery in recurrent ovarian can-
cer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO)
DESKTOP OVAR trial. Ann Surg Oncol 2006; 13(12): 1702–1710.
62. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytore-
ductive surgery in the treatment of patients with recurrent epithelial
ovarian carcinoma. Cancer 2000; 88(1): 144–153.
63. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation cri-
teria in solid tumours: Revised RECIST guideline (version 1.1). Eur J
Cancer 2009; 45(2): 228–247.
64. Rustin GJS, Vergote I, Eisenhauer E et al. Denitions for response and
progression in ovarian cancer clinical trials incorporating RECIST 1.1
and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int
J Gynecol Cancer 2011; 21(2): 419–423.
65. Bookman MA, Gilks CB, Kohn EC et al. Better therapeutic trials in ovar-
ian cancer. J Natl Cancer Inst 2014; 106(4): 1–8.
66. Ma BB, Hui EP, Mok TS. Population-based differences in treatment out-
come following anticancer drug therapies. Lancet Oncol 2010; 11(1):
75–84.
67. Fuh KC, Shin JY, Kapp DS et al. Survival differences of Asian and
Caucasian epithelial ovarian cancer patients in the United States.
Gynecol Oncol 2015; 136(3): 491–497.
68. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin
2014; 58(2): 71–96.
69. du Bois A, Floquet A, Kim J et al. Incorporation of pazopanib in main-
tenance therapy of ovarian cancer. J Clin Oncol 2014; 32(30):
3374–3382.
70. Farley JH, Tian C, Rose GS et al. Race does not impact outcome for
advanced ovarian cancer patients treated with cisplatin/paclitaxel: an
analysis of Gynecologic Oncology Group trials. Cancer 2009; 115(18):
4210–4217.
71. Soo RA, Loh M, Mok TS et al. Ethnic differences in survival outcome in
patients with advanced stage non-small cell lung cancer: results of a
meta-analysis of randomized controlled trials. J Thorac Oncol 2011;
6(6): 1030–1038.
72. Marsh S, Paul J, King CR et al. Pharmacogenetic assessment of toxicity
and outcome after platinum plus taxane chemotherapy in ovarian can-
cer: The Scottish randomised trial in ovarian cancer. J Clin Oncol 2007;
25(29): 4528–4535.
73. Brenner H, Arndt V. Recent increase in cancer survival according to age:
higher survival in all age groups, but widening age gradient. Cancer
Causes Control 2004; 15(9): 903–910.
74. Micheli A, Coebergh JW, Mugno E et al. European health systems and
cancer care. Ann Oncol 2003; 14(Suppl 5): v41–v60.
Annals of Oncology Review
Volume 28 | Issue 4 | 2017 doi:10.1093/annonc/mdx010 | 709
75. Gondos A, Holleczek B, Arndt V et al. Trends in population-based can-
cer survival in Germany: to what extent does progress reach older pa-
tients? Ann Oncol 2007; 18(7): 1253–1259.
76. Janda M, Youlden DR, Baade PD et al. Elderly patients with stage III or
IV ovarian cancer: should they receive standard care? Int J Gynecol
Cancer 2008; 18(5): 896–907.
77. Psterer J, Weber B, Reuss A et al. Randomized phase III trial of topotecan
following carboplatin and paclitaxel in rst-line treatment of advanced
ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR
and GINECO. J Natl Cancer Inst 2006; 98(15): 1036–1045.
78. du Bois A, Lück HJ, Meier W et al. A randomized clinical trial of cis-
platin/paclitaxel versus carboplatin/paclitaxel as rst-line treatment of
ovarian cancer. J Natl Cancer Inst 2003; 95(17): 1320–1329.
79. Hilpert F, Wimberger P, du Bois A et al. Treatment of elderly ovarian
cancer patients in the context of controleled clinical trials: a joint analysis
of the AGO Germany experience. Onkologie 2012; 35(3): 76–81.
80. Wells KB. Treatment research at the crossroads: the scientic interface of
clinical trials and effectiveness research. Am J Psychiatry 1999; 156(1):
5–10.
81. Rothwell PM. Factors that can affect the external validity of randomised
controlled trials. PLoS Clin Trial 2006; 1(1): e9.
82. Thrall MM, Goff BA, Symons RG et al. Thirty-day mortality after pri-
mary cytoreductive surgery for advanced ovarian cancer in the elderly.
Obstet Gynecol 2011; 118(3): 537–547.
83. Gerber DE, Laccetti AL, Xuan L et al. Impact of prior cancer on eligibil-
ity for lung cancer clinical trials. J Natl Cancer Inst 2014; 106(11):
dju302.
84. Hamaker ME, Jonker JM, de Rooij SE et al. Frailty screening methods
for predicting outcome of a comprehensive geriatric assessment in eld-
erly patients with cancer: a systematic review. Lancet Oncol 2012;
13(10): 437–444.
85. Gonzalez-Moreno S, Kusamura S, Baratti D, Deraco M. Postoperative re-
sidual disease evaluation in the locoregional treatment of peritoneal sur-
face malignancy. J Surg Oncol 2008; 98(4): 237–241.
86. Bohm S, Faruqi A, Said I et al. Chemotherapy response score: develop-
ment and validation of a system to quantify histopathologic response to
neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcin-
oma. J Clin Oncol 2015; 33(22): 2457–2463.
87. Hamanishi J, Mandai M, Iwasaki M et al. Programmed cell death 1 lig-
and 1 and tumor-inltrating CD8þ T lymphocytes are prognostic factors
of human ovarian cancer. Proc Natl Acad Sci USA 2007; 104(9):
3360–3365.
Review Annals of Oncology
710 | McGee et al. Volume 28 | Issue 4 | 2017
